UPDATE 2-Vertex Pharma's lung disorder therapy wins FDA nod

July 2 (Reuters) - Vertex Pharmaceuticals Inc's unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis.